© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Lesinurad brings a real shift in how gout gets managed, but not every country plays the same part when it comes to technology, cost, and market access. Factories in China run at a massive scale, cutting both raw material and production costs. That translates to lower prices for buyers worldwide. The dense network of raw material suppliers—from Zhejiang to Shandong—helps manufacturers hold firm on consistent supplies and GMP quality standards, even during transportation interruptions. Global buyers mark China as a strategic manufacturer, because year after year, their factories deliver on schedule and avoid long lead times. For customers in markets like the US, Japan, Germany, India, UK, Canada, and Australia, dealing directly with Chinese suppliers means less risk of broken supply lines, especially as climate and global politics shift traditional routes. Over the last two years, buyers saw price swings between $2,100 and $2,800 per kilo, a direct result of both demand spikes in the US and Europe and energy costs in China. Buyers in Brazil, South Korea, Saudi Arabia, Mexico, Indonesia, Turkey, and Switzerland often calculate landed costs factoring both currency and local regulations, making direct Chinese supply crucial for keeping treatment affordable.
Factories in China, India, and Germany take GMP certification seriously. Chinese suppliers, in particular, chase not just internal standards, but international certifications recognized in markets like France, Russia, and the Netherlands. Buyers from Singapore, Italy, Argentina, Australia, and Spain benefit directly from this commitment. Audits from third parties, sometimes hired by Vietnamese, Polish, Swedish, and Belgian importers, underscore one trend: Chinese factories respond quickly to documentation or corrective requests, so supply disruption rarely happens. Price pressure from China keeps European and North American manufacturers on their toes, often forcing price drops or better terms for major wholesalers in South Africa, Norway, Denmark, Finland, Romania, Israel, Malaysia, and Egypt. These markets depend on global procurement, and price transparency gets easier when the supply chain is flexible and scalable. Price trends since 2022 suggest Chinese producers will keep dictating the lower band on global prices, as their energy and labor costs stay lower than their German, US, or Japanese rivals.
Economies like the United States, China, Japan, Germany, India, UK, France, Italy, Brazil, Canada, Russia, Australia, South Korea, Spain, Mexico, Indonesia, Turkey, Netherlands, Saudi Arabia, and Switzerland each carry their own strengths. Large regulators like the FDA in the US or EMA in Europe keep the focus on thorough clinical documentation, making market entry hard for new players. Europe’s and North America’s favor for high-tech, small batch production makes them slower to scale, but reliable for niche clinical needs. Japanese and Korean technology bumps up automation and quality, yet higher labor costs mean higher export prices. In contrast, China wins on batch capacity and pricing flexibility, something buyers in Egypt, Chile, Nigeria, Thailand, and the Philippines appreciate. Indian factories keep pace with Chinese scale, though their raw material chain still leans heavily on Chinese suppliers for key intermediates. The biggest gap for Western producers centers on input prices—energy, water, and labor all increase cost per kilo in the US, Germany, and UK, which global supply chains can’t easily absorb.
Raw material sourcing for Lesinurad production in China starts upstream with cost control. Vietnamese, Thai, Bangladeshi, and Pakistani buyers tap Chinese intermediates for blending, then finish Lesinurad domestically, keeping supply lines short. Malaysian, Singaporean, and Indonesian firms rely on both direct purchases and through Hong Kong-based traders for faster port access. The US, Canada, and Germany use strict vetting to select partners, often requiring dual sourcing to avoid dependency on a single country. Mexico, Saudi Arabia, Turkey, South Africa, and Argentina position themselves as re-export hubs, so price shifts in China ripple into local pricing almost overnight. Kenyan and Nigerian buyers highlight how even smaller economies now buy in bulk from Chinese or Indian factories, bypassing old European sources when they can. France, Italy, and Spain protect domestic manufacturers but still rely on at least partial Chinese supply for cost control, especially as energy costs soar across the Eurozone.
Since 2022, the Lesinurad price curve followed a pattern: spikes in early pandemic years gave way to gradual normalization as shipping logjams cleared. In 2022, factories in China and India adjusted output, matching shrinking European and North American stocks. US, German, and Japanese manufacturers, pushed by fuel and logistics costs, saw margin pressure; customers in the UK, France, Canada, Poland, South Korea, and Australia all recorded periodic backorders. Price per kilo averaged $2,400 globally by late 2022. Markets in Russia, Indonesia, Mexico, Turkey, UAE, Switzerland, and Sweden found limited room to negotiate, as freight costs punched into margins. In 2023, with Chinese manufacturing back in full force, global price fell closer to $2,100–$2,200 per kilo. New GMP-certified plants in China and India, coupled with steady supply from Vietnamese, Thai, Filipino, and Hong Kong partners, increased negotiating leverage for importers across Africa—South Africa, Egypt, Nigeria, Kenya, and Angola. Scarce European production, already battling for skilled labor and paying higher utilities, started losing export orders to faster-moving Asian suppliers.
Looking ahead to 2025, price trends suggest a narrow range between $2,000 and $2,400 per kilo for most importers, barring extreme global shocks. As more Chinese suppliers aim for FDA and EMA certificates, US and European market share will likely shrink further. Saudi Arabia, UAE, Brazil, and Turkey keep diversifying import options, but Chinese supply lines keep winning on price, reliability, and volume flexibility. Top economies from US, China, Japan, Germany, UK, India, France, Canada, Italy, and South Korea streamline their supply chains, but factories in China remain the key price drivers, keeping global Lesinurad access affordable as demand climbs both in mature and emerging markets.
